type here...

CATEGORIES

Press Release

LATEST

Editors Choice

The 50 Most Influential Leaders in Pharmacy 2022 Awards

Medika Life -
Press Release

MITRE-Harris Poll Survey Finds Half of Patients in the US Feel Ignored or Doubted When Seeking Medical Treatment

Medika Life -
Digital Health

First “Global State of Digital Health Report” Tapping into 200 Million Data Points Examines More Than 12,000 Digital Health Ventures Now Available

Medika Life -
Press Release

Cumulus Neuroscience Appoints Digital Health and Pharma Executive Aman Bhatti, MD as Chief Executive Officer

Medika Life -
Anxiety and Depression

U.S. Prepares Launch of a National Three-Digit Number for the Mental Health Crisis Hotline

Medika Life -
Press Release

Walgreens Launches Clinical Trial Business to Address Industrywide Access and Diversity Challenges and Redefine Patient Experience

Medika Life -
Press Release

Largest Coordinated HIV Testing Event in the Nation on June 27th

Medika Life -
Press Release

Galien Foundation Announces New Prix Galien Award Category, “Incubators, Accelerators and Equity – Foundational Support for Health Innovation”

Medika Life -
For Doctors

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

Medika Life -
Press Release

Cogitativo Joins the Veterans Health Administration to Address the Deferred Care Challenge Using AI-Enabled Solution

Medika Life -
123...12Page 2 of 12

TRENDING

EDITORS CHOICE

Cigna Increases its Offerings to Increase Access to Care

Medika Life -
Enhanced offerings will hold down out-of pocket costs, increase support for chronic health conditions and expand access for underserved communities

Study Reveals Networks of Genes Involved in Congenital Heart Disease

Medika Life -
Over two million babies, children, and adults in the United States are living with congenital heart disease—a range of birth defects affecting the heart's structure or function

Reblozyl (luspatercept) Approved for Treatment of Transfusion-Dependent Anemia

Medika Life -
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia

Is Silmitasertib the Covid-19 Treatment Breakthrough We’ve Been Waiting for?

Medika Life -
Within 24 hours of the first dose of Silmitasertib the patient showed significant clinical improvement and the oxygen requirement was weaned to room air. The patient was discharged from the hospital five days after starting Silmitasertib.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories